EV
EVLO.US Evelo Biosciences Inc
- Market cap
- USD 1.90K
- P/E
- -
- P/B
- 3.51x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is EVLO.US undervalued?
Graham numberThe Graham number of Evelo Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evelo Biosciences Inc fundamental analysis
No fundamental analysis for Evelo Biosciences Inc yet.
Evelo Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evelo Biosciences Inc
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2…
Full company profileEvelo Biosciences Inc financial statements
Evelo Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | - | - | - | - |
| Operating Income | -13.0M | -27.5M | -58.1M | -86.4M | -91.9M | -115M | -108M | -74.3M |
| EBITDA | 495K | 834K | -56.2M | -84.6M | -89.9M | -115M | -106M | - |
| Net Income | -13.3M | -28.0M | -53.9M | -85.7M | -93.7M | -122M | -115M | -82.3M |
| EPS | -94 | -150 | -49 | -53 | -47 | -46 | -26 | - |
| Balance Sheet | ||||||||
| Total Assets | 18.6M | 43.8M | 160M | 90.9M | 90.6M | 87.9M | 64.4M | - |
| Total Liabilities | 13.0M | 14.4M | 22.9M | 30.7M | 60.2M | 79.2M | 69.4M | - |
| Shareholders' Equity | 5.53M | 29.4M | 137M | 60.2M | 30.5M | 8.67M | -4.99M | - |
| Cash & Short-term Investments | 15.5M | 38.2M | 148M | 77.8M | 68.9M | 68.4M | 47.9M | - |
| Total Debt | 9.93M | 9.97M | 12.3M | 19.6M | 40.0M | 56.3M | 51.1M | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -12.3M | -23.3M | -47.3M | -72.0M | -73.1M | -96.7M | -101M | -73.7M |
| Capital Expenditure | 1.25M | 1.74M | 5.46M | 3.03M | 1.32M | 1.52M | 622K | 287K |
| Free Cash Flow | -13.6M | -25.0M | -52.7M | -75.0M | -74.4M | -98.2M | -102M | -74.0M |
| Ratios | ||||||||
| ROE | -241.3% | -95.4% | -39.3% | -142.3% | -307.3% | -1,409.7% | - | - |
| ROA | -71.8% | -64.1% | -33.7% | -94.2% | -103.3% | -139.0% | -177.7% | - |
| Debt to Equity | 1.80x | 0.34x | 0.09x | 0.33x | 1.31x | 6.50x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Evelo Biosciences Inc dividends
Evelo Biosciences Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:20 on Jun 30, 2023.
Who owns Evelo Biosciences Inc
Top funds holding EVLO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Extended Mkt Composite | 25.3K | 0.13% | +622.68% | Sep 2023 |
| Vanguard Instl Ttl Stck Mkt Idx Tr | 2.75K | 0.01% | -97.37% | Oct 2023 |
| GF NASDAQ Bio-Tech Idx QDII RMB A | 347.00 | 0.00% | +3,370.00% | Dec 2023 |
| JHVIT Total Stock Market Index I | 129.00 | 0.00% | 0.00% | Jan 2024 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 72.00 | 0.00% | +28.57% | Jun 2023 |
Top institutions holding EVLO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Flagship Ventures Management, Inc. | 7.93M | 41.79% | +214.62% | Sep 2023 |
| Alyeska Investment Group, L.P. | 265K | 1.40% | 0.00% | Sep 2023 |
| Acadian Asset Management LLC | 47.8K | 0.25% | 0.00% | Dec 2023 |
| XTX Topco Ltd | 10.2K | 0.05% | 0.00% | Dec 2023 |
| Daiwa Securities Group Inc | 7.00 | 0.00% | 0.00% | Sep 2023 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Northern Trust Corp | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Barclays PLC | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Millennium Management LLC | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Harbourvest Partners, LLC | 0.00 | 0.00% | -100.00% | Dec 2023 |
| State Treasurer State Of Michigan | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Credit Suisse First Boston (CSFB) | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Alphabet Inc | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Royal Bank of Canada | 0.00 | 0.00% | -100.00% | Dec 2023 |
| FMR Inc | 0.00 | 0.00% | -100.00% | Dec 2023 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Dec 2023 |
Evelo Biosciences Inc company profile
- Company name
- Evelo Biosciences Inc
- Ticker
- EVLO.US
- Exchange
- USA Stocks
- Listed since
- May 9, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 66
- Fiscal year end
- December
- Address
- 600/700, One Kendall Square, Cambridge, MA, United States, 02139
- Phone
- 617 577 0300
- Website
- evelobio.com
About Evelo Biosciences Inc
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Evelo Biosciences Inc management
6- Mr. Craig R. Jalbert CIRAPresident, Secretary, Principal Executive, Financial and Accounting Officer & Director · born 1962
- Dr. Chun Zhang Ph.D.Chief Technical Operations & Quality Officer
- Ms. Leslie Wardwell-Scott Ph.D.VP and Head of Corporate Development & Strategic Integration
- Dr. Andrea Itano Ph.D.Head of Research
- Dr. Duncan McHale M.D., MBBS, Ph.D.Chief Medical Officer · born 1966
- Mr. Douglas MaslinSenior Director & Immunology Clinical Lead